Skip to main navigation
Skip to search
Skip to main content
The Hebrew University of Jerusalem Home
Approve / Request updates on publications
Home
Profiles
Research units
Research output
Prizes
Search by expertise, name or affiliation
The clinical effect of the inhibitor of apopotosis protein livin in melanoma
Itay Lazar
, Riki Perlman
, Michal Lotem
, Tamar Peretz
,
Dina Ben-Yehuda
*
, Luna Kadouri
*
Corresponding author for this work
Research output
:
Contribution to journal
›
Article
›
peer-review
31
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'The clinical effect of the inhibitor of apopotosis protein livin in melanoma'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Melanoma
100%
Clinical Effect
100%
Livin
100%
Apopotosis
100%
Livin Protein
50%
Active Disease
37%
Protein Expression
25%
Apoptotic Activity
25%
Caspase
25%
No Evidence of Disease
25%
Apoptosis
12%
Poor Prognosis
12%
Overall Survival
12%
Western Blot
12%
Protein Level
12%
Resection
12%
Median Overall Survival
12%
Truncated Forms
12%
Inhibitor of Apoptosis Proteins
12%
Favorable Prognosis
12%
Melanoma Patients
12%
Apoptosis Regulators
12%
Melanoma Vaccine
12%
Medicine and Dentistry
Melanoma
100%
Livin
100%
Diseases
41%
Overall Survival
16%
Programmed Cell Death
16%
Caspase
16%
Protein Expression
16%
Cleft
8%
Western Blot
8%
Inhibitor of Apoptosis Protein
8%
Melanoma Vaccine
8%
Pharmacology, Toxicology and Pharmaceutical Science
Melanoma
100%
Livin
100%
Diseases
41%
Overall Survival
16%
Caspase
16%
Western Blot
8%
Inhibitor of Apoptosis Protein
8%
Melanoma Vaccine
8%